The immune system is an important means to control cancer. It is also the source of hematologic malignancies. The goals of the Immunology/Immunotherapy (IMM) Program are to support basic, translational, and clinical research to improve the immune response to cancer, and to translate understanding of hematopoietic cell development into treatment of hematologic malignancies. These goals are encompassed in 3 Specific Aims: 1. to develop and optimize the efficacy of antigen-specific immunotherapeutics; 2. to understand and modulate T cell function and regulation in the tumor microenvironment; 3. to understand normal pathways of hematopoietic cell development and their dysregulation in human hematologic malignancies.
Each aim i ncludes outstanding basic science investigations, and highly collaborative translational initiatives and clinical trials. The Program co-leaders are internationally recognized for their work in tumor antigen identification, induction of tumor-specific CD8 T cell responses, and cancer immunotherapy clinical trials. The Program consists of 30 members and 7 associate members from 9 departments/divisions in the School of Medicine. Total extramural funding is over $11.17M, including over $4.04M from the NCI and over $4.77M from other NIH institutes. Program members have published 216 papers over the last 5 years, of which 12% were inter-programmatic and 16% were intraprogrammatic. The Program supports research in progress presentations and seminars to engender new directions and collaborations; pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen clinical trials led by Program members are open to enrollment across 5 cancer histologies (pancreatic cancer, breast cancer, head and neck cancer, prostate cancer, and melanoma). They include 10 investigator-initiated trials, of which three are multicenter. These trials are evaluating cancer vaccines, checkpoint blockade antibodies and combination immunotherapies. These trials test hypotheses arising from laboratory science and also bring tissue to the laboratories to investigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for continued advances in understanding of the immune system and utilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-29
Application #
9854923
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
29
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications